• 1
    Pihusch R, Salat C, Schmidt E, Goehring P, Pihusch M, Hiller E, Holler E, Kolb HJ. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 13039.
  • 2
    Bacigalupo A. Haemopoietic stem cell transplants: the impact of haemorrhagic complications. Blood Rev 2003; 17: S610.
  • 3
    Von Depka M. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Med 2002; 28: S2227.
  • 4
    Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 385864.
  • 5
    Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295304.
  • 6
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 8258.
  • 7
    McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 11622.
  • 8
    Bishop JF, Matthews JP, Yuen K, McGrath K, Wolf MM, Szer J. The definition of refractoriness to platelet transfusions. Transfus Med 1992; 2: 3541.
  • 9
    Hansen LL, Nielsen FE, Hedner U. Validation of method for determination of recombinant-FVIIa coagulant activity in plasma using a one-stage clotting assay. Thromb Haemost 1993; 69: 865.
  • 10
    Nevo S, Swan V, Enger C, Wojno KJ, Bitton R, Shabooti M, Fuller AK, Jones RJ, Braine HG, Vogelsang GB. Acute bleeding after bone marrow transplantation (BMT)-incidence and effect on survival. A quantitative analysis in 1.402 patients. Blood 1998; 91: 146977.
  • 11
    Nevo S, Enger C, Swan V, Wojno KJ, Fuller AK, Altomonte V, Braine HG, Noga SJ, Vogelsang GB. Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 1999; 67: 6819.
  • 12
    Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196201.
  • 13
    Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T For the recombinant activated factor VII intracerebral hemorrhage trial investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 77785.
  • 14
    Priftakis P, Bogdanovic G, Kokhaei P, Mellstedt H, Dalianis T. BK virus (BKV) quantification in urine samples of bone marrow transplanted patients is helpful for diagnosis of hemorrhagic cystitis, although wide individual variations exist. Clin Virol 2003; 26: 717.
  • 15
    Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 63848.
  • 16
    Pihusch R, Salat C, Gohring P, Hentrich M, Wegner H, Pihusch M, Hiller E, Kolb HJ, Ostermann H. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. Br J Haematol 2002; 117: 46976.
  • 17
    O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43: 17116.
  • 18
    Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 2015.
  • 19
    Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D, Anthuber M, Mirza DF, Kuhlman L, Bechstein WO, Diaz JC, Tartiere J, Eyraud D, Fridberg M, Erhardtsen E, Mimoz O. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005; 102: 26975.
  • 20
    Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, Cairo MS. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 18: 18591.
  • 21
    Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 433743.
  • 22
    Roberts HR, Monroe III DM, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41: 1018.
  • 23
    Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ, Holler E, Pihusch R. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78: 9118.
  • 24
    Pihusch R, Wegner H, Salat C, Pihusch M, Holler E, Kolb HJ, Hiller E. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 3817.